Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute Bioavailability and PK of Acalabrutinib in Healthy Subjects
NCT04898101Phase 1Completed
- Sponsor
- Acerta Pharma
- Start
- Mar 2016
- Primary completion
- Apr 2016
- Countries
- 1
01
Overview
Phase 1, open-label trial of acalabrutinib tablet (Variant 1) in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (2 cohorts), sponsored by Acerta Pharma. Primary endpoints: Absolute Bioavailability (F) of Acalabrutinib, Area Under the Concentration-time Curve From Hour 0 to Last Quantifiable Concentration and 7 more. Started Mar 2016; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
mantle cell lymphoma (MCL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04898101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04898101.